摘要
目的评价吉非替尼一线治疗非小细胞肺癌(NSCLC)的疗效和安全性。方法 23例NSCLC患者应用吉非替尼250mg/d,直至肿瘤进展或出现不可耐受的不良反应。将患者分为吉非替尼治疗控制组和未控制组,治疗控制组包括完全缓解(CR)、部分缓解(PR)和疾病稳定(SD);未控制组为疾病进展(PD),比较两组的临床特点和疗效。结果 23例中完全缓解(CR)0例,部分缓解(PR)12例,疾病稳定(SD)4例,疾病进展(PD)7例,疾病控制率为70%。生存期Kaplan-Meier曲线示:吉非替尼控制组较未控制组有明显的生存优势。COX回归分析示吉非替尼治疗后病情控制状况是患者生存期的影响因素,而非性别、年龄、病理类型、吸烟史。皮疹、腹泻是最主要的不良反应。结论吉非替尼一线治疗NSCLC疗效较好,可明显改善症状、提高生活质量,毒副反应轻。
Objective To evaluate the clinical efficacy and safety of gefitinib in the first line treatment of ormetastatic NSCLC.Methods Twenty-three NSCLC patients were treated with Gefitinib orally 250 mg oncedaily until disease progressi on or the occurrence of intolerablet oxicity,We grouped them into controlled（CR ＋ PR ＋ SD） or unconctrolled（PD）,compared their clinical character and difference of clinical efficacy.Results Among these 23 patients,CR 0（0%）,PR 12（52.1%）,SD 14（60.8%）,PD 7（30.4%） 1,the clinical benefit response was 70%.Kaplan-Meier show the NSCLC patients responded to gefitinib had survival benefit than those had no response.COX regression analysis showed that the effecacy of gefitinib was the influence factor of their survival（P 0.01）,while gender,age,pathologic type,and smoking history were not influence factors（P 0.05）.Conclusion Gefitinib is effective and safe in the first line treatment of patients with ormetastatic NSCLC,which can relieve symptom and improve the quality of the life.
出处
《临床肺科杂志》
2010年第12期1702-1703,共2页
Journal of Clinical Pulmonary Medicine
关键词
吉非替尼
非小细胞肺癌
疗效
Gefitinib
Non-small-cell lung cancer
Effecacy
